Table 3 Demographic and clinical characteristics of patients who received EGFR-TKI
|  | Overall [A] | Patients who received 1 L EGFR-TKI [B] | Patients who received 2 L+ EGFR-TKI [C] | P-value for [B] vs [C] |
|---|---|---|---|---|
(N = 782) | (N = 435) | (N = 347) | ||
Observation period, days, mean ± SD [median] | 371.5 ± 312.3 [309.0] | 435.5 ± 329.7 [372.0] | 291.3 ± 268.7 [220.0] | < 0.001 |
Age at metastatic NSCLC diagnosis, years, mean ± SD [median] | 67.9 ± 10.2 [69.0] | 69.4 ± 10.5 [70.0] | 66.1 ± 9.5 [66.0] | < 0.001 |
Female, n (%) | 497 (63.6) | 315 (72.4) | 182 (52.4) | < 0.001 |
Race, n (%) | ||||
 White | 440 (56.3) | 246 (56.6) | 194 (55.9) | 0.857 |
 Asian | 68 (8.7) | 43 (9.9) | 25 (7.2) | 0.186 |
 Black | 73 (9.3) | 40 (9.2) | 33 (9.5) | 0.881 |
 Other | 111 (14.2) | 56 (12.9) | 55 (15.9) | 0.236 |
 Unknown | 90 (11.5) | 50 (11.5) | 40 (11.5) | 0.988 |
Geographic region, n (%) | ||||
 Northeast | 142 (18.2) | 81 (18.6) | 61 (17.6) | 0.707 |
 West | 132 (16.9) | 76 (17.5) | 56 (16.1) | 0.621 |
 Midwest | 111 (14.2) | 51 (11.7) | 60 (17.3) | 0.027 |
 South | 284 (36.3) | 145 (33.3) | 139 (40.1) | 0.052 |
 Unknown | 107 (13.7) | 79 (18.2) | 28 (8.1) | < 0.001 |
Community-based practice, n (%) | 681 (87.1) | 359 (82.5) | 322 (92.8) | < 0.001 |
Insurance type, n (%)a,b | ||||
 Commercial Health Plan | 379 (48.5) | 198 (45.5) | 181 (52.2) | 0.065 |
 Medicare | 300 (38.4) | 169 (38.9) | 131 (37.8) | 0.754 |
 Other payer | 246 (31.5) | 127 (29.2) | 119 (34.3) | 0.127 |
 Patient assistance program | 60 (7.7) | 11 (2.5) | 49 (14.1) | < 0.001 |
 Medicaid | 47 (6.0) | 17 (3.9) | 30 (8.6) | 0.006 |
 Other government program | 31 (4.0) | 11 (2.5) | 20 (5.8) | 0.021 |
 Self pay | 7 (0.9) | 4 (0.9) | 3 (0.9) | 0.935 |
 Unknown | 115 (14.7) | 73 (16.8) | 42 (12.1) | 0.066 |
History of smoking, n (%) | ||||
 History of smoking | 493 (63.0) | 234 (53.8) | 259 (74.6) | < 0.001 |
 No history of smoking | 287 (36.7) | 199 (45.7) | 88 (25.4) | < 0.001 |
 Unknown | 2 (0.3) | 2 (0.5) | 0 (0.0) | 0.206 |
Histology at NSCLC diagnosis, n (%) | ||||
 Non-squamous cell carcinoma | 655 (83.8) | 402 (92.4) | 253 (72.9) | < 0.001 |
 Squamous cell carcinoma | 98 (12.5) | 19 (4.4) | 79 (22.8) | < 0.001 |
 NSCLC histology - not otherwise specified | 29 (3.7) | 14 (3.2) | 15 (4.3) | 0.417 |
Time from metastatic NSCLC diagnosis to index date, days, Q1 | Median | Q3 | ||||
 Overall | 44 | 202 | 478 | 22 | 62 | 336 | 177 | 328 | 553 | < 0.001 |
 Stage I-IIIA | 29 | 158 | 505 | 17 | 50 | 312 | 171 | 372 | 589 | < 0.001 |
 Stage IIIB-IV | 72 | 221 | 472 | 25 | 90 | 337 | 182 | 319 | 552 | < 0.001 |
ECOG assessment during the baseline period (including index date), n (%) | 413 (52.8) | 212 (48.7) | 201 (57.9) | 0.011 |
ECOG performance status nearest or on the index date | ||||
 0 | 126 (30.5) | 79 (37.3) | 47 (23.4) | 0.002 |
 1 | 189 (45.8) | 84 (39.6) | 105 (52.2) | 0.010 |
 2 | 82 (19.9) | 40 (18.9) | 42 (20.9) | 0.606 |
 3 | 16 (3.9) | 9 (4.2) | 7 (3.5) | 0.688 |
 4 | 0 (0.0) | 0 (0.0) | 0 (0.0) | – |
EGFR testing between the date of NSCLC diagnosis and the index date, n (%) | ||||
 Tested | 555 (71.0) | 292 (67.1) | 263 (75.8) | 0.008 |
 Positive | 355 (64.0) | 242 (82.9) | 113 (43.0) | < 0.001 |
 T790M mutation | 5 (1.4) | 3 (1.2) | 2 (1.8) | 0.693 |
 Exon 19 deletion | 141 (39.7) | 100 (41.3) | 41 (36.3) | 0.366 |
 L858R point mutation in exon 21 | 134 (37.7) | 104 (43.0) | 30 (26.5) | 0.003 |
 Double mutation | 9 (2.5) | 5 (2.1) | 4 (3.5) | 0.411 |
 Other mutation type | 48 (13.5) | 19 (7.9) | 29 (25.7) | < 0.001 |
 Unknown | 18 (5.1) | 11 (4.5) | 7 (6.2) | 0.509 |
 Negative | 175 (31.5) | 42 (14.4) | 133 (50.6) | < 0.001 |
 Results pending | 2 (0.4) | 0 (0.0) | 2 (0.8) | 0.135 |
 Unsuccessful/indeterminate test | 23 (4.1) | 8 (2.7) | 15 (5.7) | 0.080 |
Sample type among those tested | ||||
 Tissue | 482 (86.8) | 263 (90.1) | 219 (83.3) | 0.018 |
 Blood | 60 (10.8) | 20 (6.8) | 40 (15.2) | 0.002 |
 Unknown | 14 (2.5) | 10 (3.4) | 4 (1.5) | 0.153 |